Reach Pharmaceuticals Providing Emerging Therapeutics Globally
Company
News
May 2023: The TGA approved the importation of an alternative to the sugar free 40 mg trimethoprim and 200 mg sulfamethoxazole oral liquid in shortage under S19A of the Therapeutic Goods Act, 1989 until August 31, 2023. Contact Us for more details.
April 2023: The TGA approved the importation of an alternative to captopril 25 mg/5 mL oral solution under S19A of the Therapeutic Goods Act, 1989 until April 30, 2024. Contact Us for more details.
April 2023: The TGA approved the importation of an alternative to prochlorperazine mesilate 12.5mg/1mL injection ampoule under S19A of the Therapeutic Goods Act, 1989 until November 30, 2023. Contact Us for more details.
March 2023: The TGA approved the importation of DISTACLOR cefaclor 250mg/5mL granules for oral suspension (UK) under S19A of the Therapeutic Goods Act, 1989 until November 30, 2023.
January 2023: The TGA approved the importation of KEFORAL CEFALXIN 250 MG/5 ML GRANULES FOR ORAL SUSPENSION under S19A of the Therapeutic Goods Act, 1989 until December 31, 2023.
December 2022: REACH received Orphan Drug Designation for Nelarabine for infusion from the TGA in Australia.
December 2022: REACH received approval for ROMIDEPSIN-REACH powder for injection in Australia.
December 2022: The TGA approved the importation of AMOXICILLIN 125MG/5ML ORAL SUSPENSION SUGAR FREE BP (ATHLONE) under S19A of the Therapeutic Goods Act, 1989 until June 30, 2023.
November 2022: The TGA approved the importation of METRONIDAZOLE 200MG/5ML ORAL SUSPENSION (ROSEMONT) under S19A of the Therapeutic Goods Act, 1989 until February 28, 2023.
August, 2022: The TGA approved the importation of OLENA fluoxetine hydrochloride 20 mg dispersible tablet under S19A of the Therapeutic Goods Act, 1989 until November 30, 2022.
August, 2022: The TGA approved the importation of AMOXICILLIN 250MG/5ML ORAL SUSPENSION SUGAR FREE BP (KENT) under S19A of the Therapeutic Goods Act, 1989 until February 28, 2023.
July, 2022: Reach received Orphan Drug Designation for Carboprost for injection from the Therapeutic Goods Administration.
June, 2022: Our online store is now live! Visit the Shop tab to order the available products or click here.
June, 2022: Reach is pleased to announce the approval of THIOTEPA-REACH 15 mg powder for injection and THIOTEPA-REACH 100 mg powder for injection in Australia. For more details please contact us on sales@reach-pharma.com. The PI is available from the TGA website, click here
June, 2022: Reach is pleased to announce the launch of Cipla Isoprenaline for injection 0.2mg/mL, 25 ampoules and Cipla Isoprenaline for injection 1mg/5mL, 10 ampoules. For more details please contact us on sales@reach-pharma.com. The PI is available from the TGA website, click here
June, 2022: Reach is pleased to announce the launch of Metabolics Potassium Citrate 1.08g modified release tablets. For more details please contact us on sales@reach-pharma.com. The CMI is available here
January, 2022: The TGA approved the importation of Xylanaest 1% with Epinephrine 1:200,000 5ml ampoule under S19A of the Therapeutic Goods Act, 1989 until November 30, 2022.
December, 2021: The TGA approved the importation of Thiotepa for Injection, USP 15 mg AND Thiotepa for injection Injection, USP 100 mg under S19A of the Therapeutic Goods Act, 1989 until September 30, 2022.
October, 2020: Icatibant 30mg/3mL is available from Reach for supply to hospitals in Australia. The product was listed on the PBS in October. The PI is available from the TGA website, click here
June, 2020: The TGA approved the importation of Isoproterenol Hydrochloride Injection, USP 1 mg/5 mL solution for injection ampoule under S19A of the Therapeutic Goods Act, 1989 until April 30, 2022.
Source & Supply
We are actively involved in the pharmaceuticals market, to source and supply treatments globally
Market pathways
Over15 years experience in new product launches spanning from regulatory affairs to customer identification
Consultancy
Business planning, product registration and market insight
Expertise
Products
Available on the Market
Product Product Details
THIOTEPA-REACH for injection 15 mg PI, CMI
THIOTEPA-REACH for injection 100 mg PI, CMI
METABOLICS POTASSIUM CITRATE 10 MR tablets 1.08g Contact Us
ROMIDEPSIN-REACH romidepsin powder for injection PI, CMI
CIPLA ISOPRENALINE Isoprenaline for injection 0.2mg/mL PI, CMI
CIPLA ISOPRENALINE Isoprenaline for injection 1mg/5mL PI, CMI
CIPLA ICATIBANT Icatibant pre-filled syringe 30mg/3mL PI, CMI
MSN CABAZITAXEL Cabazitaxel injection 60mg/1.5mL PI, CMI
METABOLICS L-Carnitine 500 mg capsules Contact Us
Available Under Special Circumstances
Product Product Details
REAURO001 Contact Us
REAURO002 Contact Us
REAURO003 Contact Us
PRE001 Contact Us
TBRIFISO001 Contact Us
TBRIFISOPYR001 Contact Us
PYR001 Contact Us
CLOF001 Contact Us
CYC001 Contact Us
LEV001 Contact Us
PAS001 Contact Us
PRO001 Contact Us
Under Development or Regulatory Evaluation
Product Product Details
Nelarabine for infusion Contact Us
Carboprost for injection Contact Us
REACAF002 Contact Us
REACYC004 Contact Us
REACARM005 Contact Us
REACAR006 Contact Us
Reach Pharmaceuticals is an Australian privately-owned pharmaceutical company established in 2018 with a focus on marketing of innovative products that have a first to market advantage. The company also registers and supplies complex generics and other therapeutic goods formulated based on demand from clinicians.
Our pipeline includes thiotepa, potassium citrate, isoprenaline, icatibant, urokinase, carboprost and romidepsin to name a few. We have the capabilities to pursue compassionate supplies of products to fulfil shortages and manage the entire process from product identification to generation of sales.
The company is a leader in the hospital pharmaceuticals space and holds majority market share for all the products launched to date whether registered or supplied under compassionate supplies. We also have an interest in distribution of branded products and will be pursuing launch of new products in the future.
About Us
Contact Us
Location:
Ground Floor, Corporate One
84 Hotham Street
Preston VIC 3072
Email:
For medical enquiries:
Phone:
General & Sales: 0422 429 648
Medical enquiries or reporting adverse events: 1800 505 306
